Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (111-120 of 180) with videos related to

Pageof 18
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 17, 2011
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 networkGalina Lebedeva, Anatoly Sorokin, Dana Faratian, et al.
Oncotarget|October 8, 2016
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cellsHilal S Khalil, Simon P Langdon, Alexey Goltsov, et al.
British Journal of Cancer|May 1, 1992
Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cellsJ M Bartlett, G J Rabiasz, W N Scott, et al.
Seminars in Urology|November 1, 1990
Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: a decade of experienceD Raghavan, B Pearson, A Tynan, et al.
Peptides|January 1, 1995
Metabolism of the anticancer peptide H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2D A Jones, J Cummings, S P Langdon, et al.
Journal of Paediatrics and Child Health|February 1, 1996
Health care and its costs for children with perinatally acquired HIV infectionJ B Carlin, P Langdon, S F Hurley, et al.
Cancer Research|August 3, 2005
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancerKenneth Macleod, Peter Mullen, Jane Sewell, et al.
British Journal of Cancer|March 1, 1996
Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance PD A Jones, J Cummings, S P Langdon, et al.
Plos One|April 15, 2014
Increased STAT1 signaling in endocrine-resistant breast cancerRui Huang, Dana Faratian, Andrew H Sims, et al.
Cellular Signalling|September 25, 2012
Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancerHuizhong Hu, Alexey Goltsov, James L Bown, et al.
Pageof 18

Showing results (111-120 of 180) with videos related to

Sort By:
Pageof 18
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 17, 2011
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 networkGalina Lebedeva, Anatoly Sorokin, Dana Faratian, et al.
Oncotarget|October 8, 2016
A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cellsHilal S Khalil, Simon P Langdon, Alexey Goltsov, et al.
British Journal of Cancer|May 1, 1992
Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cellsJ M Bartlett, G J Rabiasz, W N Scott, et al.
Seminars in Urology|November 1, 1990
Preemptive (neoadjuvant) chemotherapy for invasive bladder cancer: a decade of experienceD Raghavan, B Pearson, A Tynan, et al.
Peptides|January 1, 1995
Metabolism of the anticancer peptide H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2D A Jones, J Cummings, S P Langdon, et al.
Journal of Paediatrics and Child Health|February 1, 1996
Health care and its costs for children with perinatally acquired HIV infectionJ B Carlin, P Langdon, S F Hurley, et al.
Cancer Research|August 3, 2005
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancerKenneth Macleod, Peter Mullen, Jane Sewell, et al.
British Journal of Cancer|March 1, 1996
Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance PD A Jones, J Cummings, S P Langdon, et al.
Plos One|April 15, 2014
Increased STAT1 signaling in endocrine-resistant breast cancerRui Huang, Dana Faratian, Andrew H Sims, et al.
Cellular Signalling|September 25, 2012
Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancerHuizhong Hu, Alexey Goltsov, James L Bown, et al.
Pageof 18